FCFrederico Costa

Frederico Costa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frederico Costa has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    External low energy electromagnetic fields affect heart dynamics: surrogate for system synchronization, chaos control and cancer patient’s health

    by Frederico P. Costa, Jack Tuszynski, Antonio F. Iemma, Willian A. Trevizan, Bertram Wiedenmann, Eckehard Schöll

    All cells in the human body, including cancer cells, possess specific electrical properties crucial for their functions. These properties are notably different between normal and cancerous cells. Cancer cells are characterized by autonomous oscillations and damped electromagnetic field (EMF) activation. Cancer reduces physiological variability, implying a systemic disconnection that desynchronizes bodily systems and their inherent random processes. The dynamics of heart rate, in this context, could reflect global physiological network instability in the sense of entrainment. Using a medical device that employs an active closed-loop system, such as administering specifically modulated EMF frequencies at targeted intervals and at low energies, we can evaluate the periodic oscillations of the heart. This procedure serves as a closed-loop control mechanism leading to a temporary alteration in plasma membrane ionic flow and the heart’s periodic oscillation dynamics. The understanding of this phenomenon is supported by computer simulations of a mathematical model, which are validated by experimental data. Heart dynamics can be quantified using difference logistic equations, and it correlates with improved overall survival rates in cancer patients.


  • Open Access

    Emerging cancer therapies: targeting physiological networks and cellular bioelectrical differences with non-thermal systemic electromagnetic fields in the human body – a comprehensive review

    by Frederico P. Costa, Bertram Wiedenmann, Eckehard Schöll, Jack Tuszynski

    A steadily increasing number of publications support the concept of physiological networks, and how cellular bioelectrical properties drive cell proliferation and cell synchronization. All cells, especially cancer cells, are known to possess characteristic electrical properties critical for physiological behavior, with major differences between normal and cancer cell counterparts. This opportunity can be explored as a novel treatment modality in Oncology. Cancer cells exhibit autonomous oscillations, deviating from normal rhythms. In this context, a shift from a static view of cellular processes is required for a better understanding of the dynamic connections between cellular metabolism, gene expression, cell signaling and membrane polarization as states in constant flux in realistic human models. In oncology, radiofrequency electromagnetic fields have produced sustained responses and improved quality of life in cancer patients with minimal side effects. This review aims to show how non-thermal systemic radiofrequency electromagnetic fields leads to promising therapeutic responses at cellular and tissue levels in humans, supporting this newly emerging cancer treatment modality with early favorable clinical experience specifically in advanced cancer.


  • Open Access

    Recurrent neurogenic shock as a rare postoperative complication associated with pancreaticoduodenectomy with mesopancreas excision in elderly patient: a case report

    by Mayara Lopes Araújo, Valentina de Almeida Carmona Tozzi, Micelange Carvalho de Souza, Luciana Beatriz Mendes Gomes, Maria Fernanda Barbosa de Medeiros, Camila Bragança Xavier, Tan Chen Wu, Marcel Autran Cesar Machado, Frederico Perego Costa

    Background: Surgical resection of locally advanced or borderline pancreatic ductal adenocarcinoma is a recognized procedure with curative intent performed in specialized oncology centers. Postoperative dysautonomia such as gastroparesis, mild hypotension, and diarrhea are common in elderly patients undergoing pancreaticoduodenectomy. A distinctive feature of our case, is the severing of an important sympathetic chain by the surgical procedure, leading to recurrent severe neurogenic shock. Locally advanced borderline tumor extension, aggressive maximal local tumor resection, and advanced age of the patient were the combined factors that explained the observed postoperative complication. Case Description: An 80-year-old woman underwent an elective R0 pancreaticoduodenectomy with total mesopancreas excision, distal gastrectomy and portal vein resection without relevant intraoperative and immediate postoperative complication. Pathology confirmed a 5.0 cm × 3.2 cm × 1.9 cm ductal adenocarcinoma in the head of the pancreas. After discharge, the patient returned to the emergency room complaining of nonspecific malaise, lipothymia, and cold sweating that was exacerbated by bowel movement attempts. During hospitalization, the patient experienced two additional severe hypotensive episodes with identical clinical presentation that required resuscitative measures in the intensive care unit (ICU). Because the third hypotensive episode developed without an obvious causal factor, apart from evacuation attempts, the hypothesis of neurogenic shock due to secondary splanchnic dysautonomia caused by extensive resection of the celiac plexus nerve structures after duodenopancreatectomy was considered. Conclusions: This discussion is important, as it enables the care team to recognize this differential diagnosis and provide the best care for the patient. The patient was treated with sympathomimetics, fludrocortisone, and mechanisms to increase venous return when clinical improvement promptly occurred, allowing discharge from the hospital. Despite the challenging prognosis of the disease, we were able to provide the patient with moments at home with their family.

  • The complexity of simplification

    by Frederico P. Costa

  • Open Access

    Low‐energy amplitude‐modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma

    by Fernanda Capareli, Frederico Costa, Jack A. Tuszynski, Micelange C. Sousa, Yone de C. Setogute, Pablo D. Lima, Luciana Carvalho, Elizabeth Santos, Brenda P. Gumz, Jorge Sabbaga, et al.

    Background: Patients with advanced hepatocellular carcinoma (HCC) and poor liver function lack effective systemic therapies. Low‐energy electromagnetic fields (EMFs) can influence cell biological processes via non‐thermal effects and may represent a new treatment option.Methods: This single‐site feasibility trial enrolled patients with advanced HCC, Child‐Pugh A and B, Eastern Cooperative Oncology Group 0–2. Patients underwent 90‐min amplitude‐modulated EMF exposure procedures every 2–4 weeks, using the AutEMdev (Autem Therapeutics). Patients could also receive standard care. The primary endpoints were safety and the identification of hemodynamic variability patterns. Exploratory endpoints included health‐related quality of life (HRQoL), overall survival (OS). and objective response rate (ORR) using RECIST v1.1.Results: Sixty‐six patients with advanced HCC received 539 AutEMdev procedures (median follow‐up, 30 months). No serious adverse events occurred during procedures. Self‐limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during EMF exposure was associated with specific amplitude‐modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment. Median OS was 11.3 months (95% confidence interval [CI]: 6.0, 16.6) overall (16.0 months [95% CI: 4.4, 27.6] and 12.0 months [6.4, 17.6] for combination therapy and monotherapy, respectively). ORR was 24.3% (32% and 17% for combination therapy and monotherapy, respectively).Conclusion: AutEMdev EMF exposure has an excellent safety profile in patients with advanced HCC. Hemodynamic alterations at personalized frequencies may represent a surrogate of anti‐tumor efficacy. NCT01686412.


  • Open Access

    Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma

    by Frederico Costa, Bertram Wiedenmann, Christoph Roderburg, Raphael Mohr, Ghassan K. Abou‐Alfa

    Hepatocellular carcinoma (HCC) is a major cause of death among patients with liver cirrhosis. The rise of immuno‐oncology has revolutionized treatment for advanced HCC. However, most pivotal randomized controlled trials have excluded patients with moderate liver dysfunction (Child–Pugh–Turcotte B), despite the high incidence of liver disease in patients with HCC at the time of diagnosis. Overall survival in patients with HCC and moderate liver dysfunction treated with sorafenib has been found to be only approximately 3–5 months, underlining the need for improved treatment algorithms for this increasingly important subgroup of patients. In this review, we summarize available data on the treatment of patients with HCC and moderate liver dysfunction. Opportunities, as well as clinical challenges, are discussed in detail, highlighting potential changes to the therapeutic landscape.


  • Open Access

    Supplementary Tables from Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study

    by Angela Lamarca, Maxime Ronot, Salma Moalla, Joakim Crona, Marta Opalinska, Carlos Lopez Lopez, Daniela Pezzutti, Pavan Najran, Luciana Carvhalo, Regis Otaviano Franca Bezerra, et al.

    Supplementary Table 1: Baseline characteristics of patients for external validation (Aim-2). Supplementary Table 2: Univariate and Multivariable Cox regression for Progression-Free Survival (Aim-2).

  • Open Access

    Supplementary Tables from Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study

    by Angela Lamarca, Maxime Ronot, Salma Moalla, Joakim Crona, Marta Opalinska, Carlos Lopez Lopez, Daniela Pezzutti, Pavan Najran, Luciana Carvhalo, Regis Otaviano Franca Bezerra, et al.

    Supplementary Table 1: Baseline characteristics of patients for external validation (Aim-2). Supplementary Table 2: Univariate and Multivariable Cox regression for Progression-Free Survival (Aim-2).

  • Open Access

    Data from Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study

    by Angela Lamarca, Maxime Ronot, Salma Moalla, Joakim Crona, Marta Opalinska, Carlos Lopez Lopez, Daniela Pezzutti, Pavan Najran, Luciana Carvhalo, Regis Otaviano Franca Bezerra, et al.

    Purpose:Tumor growth rate (TGR) represents the percentage change in tumor volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in neuroendocrine tumors (NET).Experimental Design:Patients from 7 centers with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST/WW were eligible. Computed tomography (CT)/MRI performed at prebaseline, baseline, and 3(±1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR3m-BL; paired T test), and Aim-2: validate TGR3m (<0.8%/m vs. ≥0.8%/m) as an early biomarker in an independent cohort (Kaplan–Meier/Cox regression).Results:Of 785 patients screened, 127 were eligible. Mean (SD) TGR0 and TGR3m were 5.4%/m (14.9) and −1.4%/m (11.8), respectively. Mean (SD) ΔTGR3m-BL paired-difference was −6.8%/m (19.3; P < 0.001). Most marked ΔTGR3m-BL [mean (SD)] were identified with targeted therapies [−11.3%/m (4.7); P = 0.0237] and chemotherapy [−7.9%/m (3.4); P = 0.0261]. Multivariable analysis confirmed the absence of previous treatment (OR = 4.65; 95% CI, 1.31–16.52; P = 0.018) and low TGR3m (continuous variable; OR 1.09; 95% CI, 1.01–1.19; P = 0.042) to be independent predictors of radiologic objective response. When the multivariable survival analysis for PFS (Cox regression) was adjusted to grade (P = 0.004) and stage (P = 0.017), TGR3m ≥ 0.8 (vs. <0.8) maintained its significance as a prognostic factor (P < 0.001), whereas TGR0 and ΔTGR3m-BL did not. TGR3m ≥ 0.8%/m was confirmed as an independent prognostic factor for PFS [external validation; Aim-2; multivariable HR 2.21 (95% CI, 1.21–3.70; P = 0.003)].Conclusions:TGR has a role as a biomarker for monitoring response to therapy for early identification of treatment-induced changes and for early prediction of PFS and radiologic objective response.

  • Open Access

    Data from Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study

    by Angela Lamarca, Maxime Ronot, Salma Moalla, Joakim Crona, Marta Opalinska, Carlos Lopez Lopez, Daniela Pezzutti, Pavan Najran, Luciana Carvhalo, Regis Otaviano Franca Bezerra, et al.

    Purpose:Tumor growth rate (TGR) represents the percentage change in tumor volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in neuroendocrine tumors (NET).Experimental Design:Patients from 7 centers with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST/WW were eligible. Computed tomography (CT)/MRI performed at prebaseline, baseline, and 3(±1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR3m-BL; paired T test), and Aim-2: validate TGR3m (<0.8%/m vs. ≥0.8%/m) as an early biomarker in an independent cohort (Kaplan–Meier/Cox regression).Results:Of 785 patients screened, 127 were eligible. Mean (SD) TGR0 and TGR3m were 5.4%/m (14.9) and −1.4%/m (11.8), respectively. Mean (SD) ΔTGR3m-BL paired-difference was −6.8%/m (19.3; P < 0.001). Most marked ΔTGR3m-BL [mean (SD)] were identified with targeted therapies [−11.3%/m (4.7); P = 0.0237] and chemotherapy [−7.9%/m (3.4); P = 0.0261]. Multivariable analysis confirmed the absence of previous treatment (OR = 4.65; 95% CI, 1.31–16.52; P = 0.018) and low TGR3m (continuous variable; OR 1.09; 95% CI, 1.01–1.19; P = 0.042) to be independent predictors of radiologic objective response. When the multivariable survival analysis for PFS (Cox regression) was adjusted to grade (P = 0.004) and stage (P = 0.017), TGR3m ≥ 0.8 (vs. <0.8) maintained its significance as a prognostic factor (P < 0.001), whereas TGR0 and ΔTGR3m-BL did not. TGR3m ≥ 0.8%/m was confirmed as an independent prognostic factor for PFS [external validation; Aim-2; multivariable HR 2.21 (95% CI, 1.21–3.70; P = 0.003)].Conclusions:TGR has a role as a biomarker for monitoring response to therapy for early identification of treatment-induced changes and for early prediction of PFS and radiologic objective response.